new concerns about using selegiline (Eldepryl) for patients with early Parkinson's disease
April 1996
There are new concerns about using selegiline (Eldepryl) for patients with early Parkinson's disease.
A surprising British study suggests that adding selegiline to levodopa therapy doesn't slow the progression of Parkinson's...and might increase mortality.
But tell patients not to panic...many experts dispute these findings and say the study was flawed. They say that selegiline DOES help certain patients...by improving symptoms and having a levodopa-sparing effect.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote